S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
LON:AMYT

Amryt Pharma - AMYT Share Forecast, Price & News

GBX 143
-19.00 (-11.73%)
(As of 01/10/2022)
Add
Compare
Today's Range
143
▼
155
50-Day Range
143
▼
143
52-Week Range
135
▼
230
Volume
90,727 shs
Average Volume
469,552 shs
Market Capitalization
£457.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

AMYT stock logo

About Amryt Pharma (LON:AMYT) Stock

Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Receive AMYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter.

AMYT Stock News Headlines

March 22, 2023 | finance.yahoo.com
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
January 16, 2023 | msn.com
Chiesi Farmaceutici S.p.A. to acquire Amryt Pharma
March 28, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
January 10, 2023 | benzinga.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Amryt Pharma Plc Buyout
January 9, 2023 | benzinga.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMYT, CINC, ALBO
January 9, 2023 | technews.tmcnet.com
AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders
January 8, 2023 | au.finance.yahoo.com
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
December 5, 2022 | ca.finance.yahoo.com
European Commission approves Mycapssa® for the treatment of Acromegaly
March 28, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
October 31, 2022 | nz.finance.yahoo.com
Amryt Supports Acromegaly Awareness Day 2022
October 17, 2022 | finance.yahoo.com
Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)
October 15, 2022 | seekingalpha.com
AMYT Amryt Pharma plc
August 6, 2022 | seekingalpha.com
Amryt Pharma plc (AMYT) CEO Joseph Wiley on Q2 2022 Results - Earnings Call Transcript
August 4, 2022 | finance.yahoo.com
Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue Estimates
July 30, 2022 | morningstar.com
Amryt Pharma PLC ADR Stock Quote AMYT
June 27, 2022 | seekingalpha.com
Amryt Pharma appoints Dr Tracy Cunningham as Chief Medical Officer
June 25, 2022 | marketwatch.com
Amryt to Pursue Formal FDA Resolution for Oleogel-S10 >AMYT
June 24, 2022 | finance.yahoo.com
Filsuvez's European Approval Adds Growth Driver For Amryt Pharma
June 24, 2022 | nasdaq.com
Amryt Pharma To Submit Formal Dispute Resolution Request For Oleogel-S10 NDA
May 17, 2022 | finance.yahoo.com
Amryt Announces Details of EMA Contingent Value Rights Payment
May 11, 2022 | uk.finance.yahoo.com
Amryt Announces New Patent for Mycapssa®
May 8, 2022 | seekingalpha.com
Amryt Pharma PLC (AMYT) CEO Joseph Wiley on Q1 2022 Results - Earnings Call Transcript
April 22, 2022 | seekingalpha.com
Amryt stock rises 10% as EMA panel backs approval of Filsuvez to treat skin disorder in EU
April 13, 2022 | finance.yahoo.com
Amryt Posts Long-Term Safety, Efficacy Mycapssa Data In Acromegaly Patients
March 17, 2022 | nasdaq.com
Amryt Pharma PLC Rings the Opening Bell
March 8, 2022 | tmcnet.com
The Law Offices of Frank R. Cruz Announces Investigation of Amryt Pharma plc (AMYT) on Behalf of Investors
March 8, 2022 | benzinga.com
A Preview Of Amryt Pharma's Earnings
See More Headlines
Receive AMYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:AMYT
Previous Symbol
LON:FAST
CUSIP
N/A
CIK
N/A
Web
www.amrytpharma.com
Phone
+44-20-34155730
Fax
N/A
Employees
2,020
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
66.05
Current Ratio
1.80
Quick Ratio
1.14

Sales & Book Value

Annual Sales
£210.24 million
Price / Sales
2.17
Cash Flow
GBX 38.90 per share
Price / Cash Flow
3.68
Book Value
GBX 96.60 per share
Price / Book
1.48

Miscellaneous

Outstanding Shares
319,657,000
Free Float
N/A
Market Cap
£457.11 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Joseph A. Wiley (Age 50)
    CEO & Director
    Comp: $1.72M
  • Mr. Rory P. Nealon (Age 53)
    CFO, COO & Company Sec.
    Comp: $931k
  • Ms. Elizabeth Varki Jobes J.D. (Age 54)
    Sr. VP & Global Chief Compliance Officer
  • Mr. John McEvoy
    Gen. Counsel
  • Mr. Stephen Joyce
    VP of Global Marketing
  • Ms. Julie Eastwood
    Head of HR
  • Ms. Derval O'Carroll
    Head of Regulatory Affairs
  • Mr. Gerry Gilligan
    Head of Manufacturing Supply Chain
  • Dr. Mark Sumeray (Age 55)
    Chief Medical Officer
  • Mr. David Allmond
    Chief Commercial Officer

Key Competitors

View All Competitors













AMYT Stock - Frequently Asked Questions

How have AMYT shares performed in 2023?

Amryt Pharma's stock was trading at GBX 143 at the beginning of the year. Since then, AMYT stock has increased by 0.0% and is now trading at GBX 143.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Amryt Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include The Parkmead Group (PMG), Himax Technologies (HIMX), Atalaya Mining (ATYM), Concepta PLC (CPT.L) (CPT), Faroe Petroleum (FPM), Vectura Group (VEC), Xcite Energy (XEL), Bowleven (BLVN), BTG (BTG) and Cavium (CAVM).

What is Amryt Pharma's stock symbol?

Amryt Pharma trades on the London Stock Exchange (LON) under the ticker symbol "AMYT."

How do I buy shares of Amryt Pharma?

Shares of AMYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Amryt Pharma's stock price today?

One share of AMYT stock can currently be purchased for approximately GBX 143.

How much money does Amryt Pharma make?

Amryt Pharma (LON:AMYT) has a market capitalization of £457.11 million and generates £210.24 million in revenue each year.

How many employees does Amryt Pharma have?

The company employs 2,020 workers across the globe.

How can I contact Amryt Pharma?

Amryt Pharma's mailing address is Ivybridge House, 1 Adam Street, LONDON, WC2N 6LE, United Kingdom. The official website for the company is www.amrytpharma.com. The company can be reached via phone at +44-20-34155730.

This page (LON:AMYT) was last updated on 3/28/2023 by MarketBeat.com Staff